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Cytochrome bc1 is a proven drug target in the prevention and
treatment of malaria. The rise in drug-resistant strains of Plasmo-
dium falciparum, the organism responsible for malaria, has gener-
ated a global effort in designing new classes of drugs. Much of the
design/redesign work on overcoming this resistance has been fo-
cused on compounds that are presumed to bind the Qo site (one of
two potential binding sites within cytochrome bc1) using the
known crystal structure of this large membrane-bound macromo-
lecular complex via in silico modeling. Cocrystallization of the cy-
tochrome bc1 complex with the 4(1H)-pyridone class of inhibitors,
GSK932121 and GW844520, that have been shown to be potent
antimalarial agents in vivo, revealed that these inhibitors do not
bind at the Qo site but bind at the Qi site. The discovery that these
compounds bind at the Qi site may provide a molecular explana-
tion for the cardiotoxicity and eventual failure of GSK932121 in
phase-1 clinical trial and highlight the need for direct experimental
observation of a compound bound to a target site before chemical
optimization and development for clinical trials. The binding of
the 4(1H)-pyridone class of inhibitors to Qi also explains the ability
of this class to overcome parasite Qo-based atovaquone resistance
and provides critical structural information for future design of
new selective compounds with improved safety profiles.
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Malaria is a major health problem in many parts of theworld. In 2012 there were an estimated 219 million cases,
from which there were over half a million deaths, the majority of
which were pregnant women and children under 5 (1). Eradication
programs have had some success in reducing malaria mortality
through targeting the mosquito vector Anopheles gambiae and the
development of a Plasmodium vaccine continues to show promise
(2–4). Despite this success, incidence of chloroquine, artemisinin,
and multidrug resistant strains of the Plasmodium parasite and of
Plasmodium falciparum, the most lethal strains of malaria, have
been reported and appear to be rising (5–7). Individual com-
pounds used in monotherapy frequently suffer resistance, resulting
in the need for expensive combinatorial treatments (8–10). This
situation calls for new, cost-effective, drugs that can contribute
toward more effective treatment and eventual eradication.
Cytochrome bc1 (ubiquinol: cytochrome c oxidoreductase;
complex III) is a major drug target for the treatment and pre-
vention of malaria, and in the treatment of toxoplasmosis (8, 11).
Cytochrome bc1 is a dimeric multisubunit electron transport
protein embedded in the inner-mitochondrial membrane (12–
14). There are three catalytic subunits: cytochrome b, cyto-
chrome c1, and the Rieske iron–sulfur protein, which are present
in all bc1 complexes (12). The complex forms part of the re-
spiratory chain and acts to transport H+ into the intermembrane
space through the oxidation and reduction of ubiquinone in the
modified Q cycle (12, 15, 16). The Q cycle requires two distinct
binding sites for the reduction and oxidation of ubiquinol and
ubiquinone. Both sites are located within cytochrome b; the Qo
site acts to oxidize ubiquinol near the intermembrane space (17),
and the Qi site binds and reduces ubiquinone near the mito-
chondrial matrix. In P. falciparum, cytochrome bc1 is essential to
ensure a pool of oxidized ubiquinone for use by dihydroorotate
dehydrogenase (DHODH) in pyrimidine biosynthesis; inhibition
of cytochrome bc1 or DHODH leads to parasite death (18, 19).
Atovaquone, a hydroxynapthoquinone (Fig. 1), binds cytochrome
bc1 at the Qo site (20, 21). It is used as a fixed-dose combination
with proguanil (marketed as Malarone) for treating children and
adults with uncomplicated malaria or as chemoprophylaxis for
preventing malaria in travelers. In the United States, between
2009 and 2011, Malarone prescriptions accounted for 70% of all
antimalarial pretravel prescriptions (22).
Several mutations, giving rise to atovaquone-resistant strains of
P. falciparum and Toxoplasma gondii, have been reported since
the turn of the century (23–27). These mutations arise in the Qo
pocket and prevent atovaquone from binding (28). A recent X-ray
structure of cytochrome bc1 from Saccharomyces cerevisiae has
shown atovaquone bound in the catalytic Qo site, offering expla-
nation for the cross-species resistance (20). Many different classes
of compound have been investigated as potential drugs and much
work has focused on inhibition of the Qo site (23, 29–32). The
4(1H)-pyridones have been researched for their antimalarial prop-
erties since the 1960s, based on the compound clopidol (33, 34)
(Fig. 1). GW844520 produced by GlaxoSmithKline (GSK) was
found to have excellent antimalarial drug properties, even against
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atovaquone-resistant parasites, but had to be withdrawn from
development due to unexpected toxicity (35). GSK932121 was
also found to have strong antimalarial properties, including
against atovaquone-resistant parasites (36), and progressed to a
first time in human (FTIH) study. However, during the FTIH
study, a phosphate-prodrug backup of GSK932121 was observed
to result in unexpected acute toxicity in rats after oral adminis-
tration, which was subsequently replicated by dosing GSK932121
alone through i.p. administration at similar exposure levels to
those achieved with its prodrug. The observed acute toxicity
resulted in the immediate termination of the FTIH study and
was attributed to cardiotoxicity, possibly via the inhibition of the
mammalian bc1 (37). It was concluded that these compounds
may bind to the Qo site of cytochrome bc1 in a novel way to
overcome atovaquone resistance.
The Qi site of cytochrome bc1 has been far less explored in the
search for antimalarial compounds and only the binding of a few
compounds has been visualized directly (38–40). Several com-
pounds have been suggested to bind the Qi site, including po-
tential antimalarial compounds, but due to lack of structural
information have not been pursued vigorously (41). Here we
provide the structure of bovine heart cytochrome bc1 complex with
4(1H)-pyridone compounds, GW844520 and GSK932121. The
crystallographic structures provide clear evidence of these com-
pounds unexpectedly bound in the Qi site. This discovery explains
the ability of this class to overcome parasite atovaquone resistance
and provides critical structural information for the future design of
new selective compounds with reduced/no toxicity.
Results
The Pyridones GSK932121 and GW844520 Bind to Qi Site of Cytochrome
bc1. Structures of cytochrome bc1 complexes from multiple
organisms bound to various compounds have been previously
published (14, 38, 42, 43). The majority of these compounds are
bound to the Qo site in various conformations (44). The pyridones
GSK932121 and GW844520 had been suggested to bind bovine
cytochrome bc1 at the Qo site through mutation and chemical-
binding studies (29). Electron density was clearly visible within the
Qi site and each of the pyridones fit accurately (Fig. 2). The Qi
binding site is located within the transmembrane region of cyto-
chrome bc1 and is formed by residues of transmembrane helices A,
D, and E as well as helix a and the heme bH (14, 45). It is ac-
cessible through a hydrophobic channel, which terminates at heme
bH and several polar residues (Fig. 3). The binding of both
GSK932121 and GW844520 appears very similar with the head
group of both molecules binding close to heme bH and the tail
extending out of the channel away from the heme (Fig. 3C).
The head of the compound was placed unambiguously in
a plane according to the omit Fo-Fc density and oriented so that
the amine of the pyridone and the N of His201 on helix D (Fig.
2) were within bonding range. The carbonyl of both GW844520
and GSK932121 was within 3.5 Å of both Ser35 on loop A and
OD1 of Asp228 on loop E to allow forming of H bonds (Fig. 3C).
After refinement with the compounds, additional electron den-
sity became visible, allowing positioning of the triflouromethyl
tail group between Met190 and Met194. There was visible den-
sity along the first phenyl group of the hydrophobic tail of each
compound. Residues Phe18, Leu21, and Leu197 form a tight
hydrophobic pocket around the aromatic rings of the pyridone
tail while Phe220 appears to form a stacking interaction with the
head group suggesting hydrophobic interactions provide a large
part of the binding energy (Fig. 3C). No density was visible in
the Qo site confirming that these compounds bind solely to
the Qi site.
Residue Differences in Binding Pocket. The protein sequence
alignment of bovine, human, and P. falciparum cytochrome
b shows a fairly conserved Qi binding site (Fig. 4C). However,
there are differences in the N-terminal region of cytochrome
b between the mammalian protein and the Plasmodium homo-
log. The protein is shorter in both T. gondii and Plasmodia. Both
Phe18 and Leu21 of the surface loop before helix A, which forms
a hydrophobic pocket around the aromatic tail of the 4(1H)-
pyridones, are replaced with Leu and Tyr, respectively, in both P.
Fig. 1. Chemical structures of relevant compounds. Ubiquinol binds both the
Qo and Qi site of cytochrome bc1 in the modified Q cycle. Atovaquone,
a hydroxynapthoquinone, is a known binder of the cytochrome bc1 Qo site.
Clopidol is a known treatment for malaria and is the basis for the pyridone
class of compound, including GW844520 and GSK932121. GSK932121 has
a substituted alkyl group located on the head compared with GW844520.
Fig. 2. Cytochrome bc1 Qi binding site occupied by 4(1H)-pyridones. The
Fo-Fc and 2Fo-Fc electron density maps are shown in green and blue at 3σ and
1σ, respectively. (A and B) Present data for the GW844520 complex; (C and D)
for the GSK932121 complex. The electron density is clearly visible around
compound and surrounding residues involved in binding, including heme bH,
His203, and Phe222.
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falciparum and T. gondii, which would suggest large differences
in the binding around the tail groups of both compounds. Ala191
allows a large opening in the cavity toward the terminus of the Qi
site but is replaced by a Cys residue in the parasite. Both Met190
and Met194 are nonconserved between all of the sequences
aligned, whereas Gly204 and Ser205 are conserved. Ser205 has
been shown to be involved in the binding of ubiquinone (44).
Phe220 is conserved across cytochrome b sequences and is
thought to be important in forming an interaction with the ar-
omatic pyridone head group, whereas Leu201 located on the
opposite side to Phe220 is conserved in both the parasite and
human protein.
Cellular Toxicity of GW844520 and GSK932121 Is Associated with
Mitochondrial Dysfunction. Mitochondrial toxicity can be identi-
fied by the differing responses observed for HepG2 cells grown in
glucose-containing media, which favors glycolysis, or galactose-
containing media, which promotes reliance upon oxidative
phosphorylation (46). As an exemplar, the toxicity of tamoxifen is
observed to be unaltered by a change of growth media, as is
expected for a compound with no known mitochondrial toxicity
(Fig. 5A). Conversely, the mitochondrial complex I (NADH:
quinone oxidoreducatse) inhibitor rotenone is not significantly
toxic in glucose media but demonstrates severe toxicity in galac-
tose media (Fig. 5B), thus indicting disruption of oxidative
phosphorylation. Both GW844520 and GSK932121 (Fig. 5 C and
D) displayed significantly enhanced toxicity in the galactose me-
dium, indicative of mitochondrial-based toxicity. However, the
next generation 4(1H)-quinolone-3-diarylether ELQ 300 (30) and
2-aryl quinolone SL-2-25 (47) did not show significant enhance-
ment of toxicity in galactose-grown HepG2 (Fig. 5 E and F).
Molecular Docking. Molecular docking was performed using the
coordinates of the cocrystallized structures of bovine bc1 com-
plex reported here. A protocol was developed and validated,
which is able to reproduce the crystallographic binding modes of
both GW844520 and GSK932121 (Fig. 6). The docked model and
experimental structures showed excellent agreement (rmsd < 2 Å)
for both GSK932121 and GW844520 (Fig. 6). This protocol was
also applied to predict the binding poses for antimycin A,
a compound known to bind to the Qi site, as a control (42).
Atovaquone that has been shown not to bind to the Qi site was
also used as a control. The docking for antimycin A was able to
reproduce the X-ray crystallographic binding pose (rmsd 1.67 Å)
and forms a very similar array of noncovalent interactions with
the protein as GSK932121 and GW844520. In contrast, atova-
quone did not produce consistent docking poses in the Qi
binding site (data not shown). These facts indicate the robust
nature of the docking protocol used in the light of new structures
and show the potential for its use for further development of
compounds. The next generation compounds, namely ELQ 300
and SL-2-25, showed their binding to the Qi site.
Discussion
The structural details of cocrystallized bovine cytochrome bc1
complex and compounds GW844520 and GSK932121 show sim-
ilar binding modes in the Qi pocket (Fig. 2), suggesting that this
binding mode is likely to prevail in the family of 4(1H)-pyridone
compounds. The formation of hydrogen bonds between several
residues and the head group of each compound means that these
are strongly bound at the end of the channel, 12 Å away from the
center of heme bH. The head forms several electrostatic inter-
actions. Ne2 of His201 is pointed directly at the amide of the
pyridone head and is separated by 3.3 Å. Ser205 and Asp228
on helix E are 2.9 Å and 2.7 Å from the carbonyl group, re-
spectively, which is common among many Qi binding ligands.
These residues are also found to interact directly with the head
of antimycin and ubiquinone, which lie in a similar position deep
within this cavity (38, 42). The chlorine atom is 4.3 Å away
from the carboxyl of Trp31 and is largely surrounded by ali-
phatic residues in a hydrophobic space. The change from
a methyl group at position 6 in GW844520 to an alkyl group
in GSK932121 shows little difference in the electron density;
however, it does appear within 3 Å of the carbonyl of the peptide
bond in Ala17. Ala17 forms part of the N-terminal region that
Fig. 3. Binding of GW844520 and GSK932121 within the hydrophobic Qi
cavity. (A) Surface view of cytochrome bc1 in complex with GSK932121
(green) and GW844520 (yellow) colored by hydrophobicity: more hydro-
phobic residues are red, more polar residues are white. (B) View of the
binding site: the hydrophobic tail of each compound lies along the cavity,
keeping close to the hydrophobic surface, whereas the head binds near the
heme in a polar environment. (C) Two-dimensional pharmacophore of the
various interactions between the Qi binding site and both pyridone com-
pounds: GW844520 in the foreground, GW844520 in gray in the rear. Spe-
cific atoms are colored accordingly: carbon in black, oxygen in red, nitrogen
in blue, and halogens in green (produced using Ligplot) (53).
Fig. 4. The conservation of the residues involved in the Qi site: inhibitor
binding shows opportunities for future drug design. Residues fully conserved
between human and malaria are colored in deep blue, partially conserved in
light blue, and unconserved in white. Residues not involved in Qi site binding
are colored in gray. The structural details of (A) the tail binding region and
(B) head binding for both GW844520 (orange) and GSK932121 (yellow). (C)
Protein sequence alignment between bovine, human, S. cerevisiae, P. falciparum,
and T. gondii showing conservation in the Qi binding site. Scale at the Top is
numbered according to bovine sequence.
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is not conserved in Plasmodia parasites (Fig. 4), which may
help to explain differences in binding between mammalian and
parasite complexes.
The tail of each compound proceeds away from heme bH and
directly down toward the entrance of the cavity between cyto-
chrome bc1 monomers. The tail region appears more flexible in
GSK932121, perhaps due to alternate location of the tri-
fluoromethyl group (Fig. 1) no longer being able to interact with
Met194. Phe18 can be seen forming a stacking interaction with
both phenyl rings of the tail, which may help fix the pyridone
compounds in place as opposed to the lack of density that was
seen in ubiquinone-bound structures (38). This would help ex-
plain the increased strength of binding in the pyridones com-
pared with ubiquinone.
Reversing the Crabtree effect in HepG2 cells by switching to
a galactose carbon source can be shown to clearly discriminate
between nonmitochondrial (e.g., tamoxifen; Fig. 5A) and mito-
chondrial (e.g., rotenone; Fig. 5B) inhibitors. Consistent with the
presented cocrystallized structural data of GSK932121 and
GW844520 bound to bovine bc1 and the hypothesis that the
acute in vivo toxicity seen in this pyridone class is of mitochon-
drial origin (37), both GSK932121 and GW844520 display sig-
nificantly enhanced toxicity in galactose media (Fig. 5 C and D).
The next generation 4(1H)-quinolone-3-diarylether ELQ 300
(30) and 2-aryl quinolone SL-2-25 (47) did not show significant
enhancement of toxicity in galactose-grown HepG2 (Fig. 5 E and
F), suggesting that these preferentially target Plasmodium bc1.
These data are consistent with human and bovine bc1 sensitivity
data previously reported (30, 47).
As noted, it has been generally accepted that the 4(1H)-pyr-
idone class, e.g., GW844520, targets the Qo oxidation site of the
bc1 complex, via analogy with the mechanism of action of the Qo
targeted antimalarial atovaquone, and indeed models of the
pyridone/bc1 Qo interaction of these molecules have been pre-
viously described (33). The next generation bc1 inhibitor quino-
lone, ELQ 300, was designed by replacement of the pyridone
unit of GW844520, with a quinolone group as shown (Fig. 1),
and the close similarity of these two antimalarials would suggest,
based on the GSK model, that the Qo site is the likely molecular
target. Here, using docking, we show that ELQ 300 and SL-2-25
bind well at the Qi site, suggesting an alternative target site/
mechanism to atovaquone.
This modeling observation is consistent with our recent studies
on the quinolone 1-hydroxy-2-dodecyl- 4(1H)quinolone (HDQ)
in yeast models (41). Introduction of point mutations into the Qi
site, namely G33A, H204Y, M221Q, and K228M, markedly de-
creased HDQ inhibition; by contrast, known inhibitor resistance
mutations at the Qo site did not cause HDQ resistance. A recent
study in T. gondii showed that mutations at the Qi site of yeast
cytochrome b reduced the growth inhibition effect of ELQ 271
(48). Taken together, these data indicate that the Qi site of the
bc1 complex is the likely target for a number of next generation
ubiquinone-mimicking antimalarials that are not cross-resistant
with atovaquone. In support of this finding, the docking poses of
both ELQ 300 and SL-2-25 molecules were similar, with the
quinolone head groups both bound at the end of the pocket
defined by His201, Ser205, Asp228, and Ser35 of cytochrome
b with the long hydrophobic tails of the compounds directed
toward the region defined by Met190, Met194, and Ile42 (anal-
ogous with GSK932121 and GW844520).
Although cytochrome b appears to be highly conserved across
phyla, the differences between cytochrome b in members of the
Plasmodia family compared with human appear significant from
sequence alignment. The N-terminal region appears consider-
ably shorter, which is likely to result in a considerably different
opening to the Qi cavity and binding site. This difference in
primary structure could open up the tail region of the pyridone
compounds to more specific binding, preventing cross-reactivity
between pathogen and host. Interestingly, the fluorine atom of
GW844520 appears bound next to Met194, which is only present
in the bovine cytochrome b protein. This could explain the higher
IC50 reported for bovine cytochrome bc1 compared with the hu-
man (29), despite the high conservation in their sequence. In
the Plasmodia protein, Met194 is substituted by a Phe residue
(Fig. 4C), which could allow for specific compound modifications
to be made to increase binding. Phe18 is another promising tail
region residue for drug design, as in the Plasmodia sequence, it is
substituted for a Leu. Within the head group of the binding site,
Ser205, which binds the carbonyl of both pyridone molecules, is
replaced with a Phe residue. It is difficult to estimate what would
Fig. 5. Determining the site of toxicity of the 4(1H)-pyridones and next
generation quinolones. By reversing the Crabtree effect using HepG2 cells
grown on galactose, it is possible to demonstrate that compounds (A) ta-
moxifen, (E) ELQ 300, and (F) SL-2-25 do not greatly affect viability through
oxidative phosphorylation. Compounds (B) rotenone, (C) GW844520, and
(D) GSK932121 significantly disrupt oxidative phosphorylation. Data show
averages from independent experiments (n ≥ 3), ±SD. The IC50 values were
determined using a four-parameter logistic function.
Fig. 6. Comparison of the ligand’s docking poses with the conformation from
X-ray crystal structures (A) GSK932121 and (B) GW844520. (rmsd GSK932121
1.634 Å and GW844520 1.762 Å). Molecules are rendered as sticks colored by
atom type (carbon docking, light gray; carbon crystal structure, cyan; chlorine,
green; oxygen, red; and fluorine, light blue).
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happen within the binding site, but this difference may go some
way to explaining why binding within the parasite is an order of
magnitude stronger than in bovine (29).
Work on improving the clinically promising 4(1H)-pyridones so
far has lacked structural information (33, 34). The elucidation of
4(1H)-pyridone binding within the Qi site of mitochondrial cyto-
chrome bc1 complex provides for the first time to our knowledge
an opportunity for rational drug design to increase selectivity
against Plasmodia parasites toward novel treatments and reducing
transmission. The overwhelming importance of direct observation
of drug leads at their target sites is highlighted in this study. In situ
visualization of drug candidates by experimental structural meth-
ods such as X-ray crystallography should be built in as the gold
standard for validation of binding of these compounds before
optimization in a drug-discovery pipeline.
Materials and Methods
Preparation of Crude Protein. Isolation of crude mitochondria was carried out
as previously reported in the following method (14). Briefly, bovine heart
muscle was homogenized in a Waring blender and added at a ratio of 2 L
buffer (250 mM sucrose; 20 mM K2HPO4; 2 mM succinic acid; 0.5 mM EDTA)
per 500 g of muscle tissue. The homogenate was subjected to centrifugation
at 1,500 × g for 20 min and the supernatant was then further centrifuged at
23,500 × g for 20 min. The pellet, containing bovine mitochondria, was
collected and washed in wash buffer 1 (50 mM KPi pH 7.5; 0.1 mM PMSF).
The mitochondrial pellet was resuspended in wash buffer 2 (50 mM KPi pH
7.5; 250 mM NaCl; 3 mM NaN3; 0.1 mM PMSF). The amount of protein was
quantified using a BCA (bicinchoninic acid) assay (Pierce). The remaining
solution was centrifuged at 180,000 × g for 60 min and the pellet was
resuspended in the same wash buffer, with the addition 0.1 mg n-dodecyl β-D-
maltopyranoside (DDM) per 1 mg of protein. The solution was centrifuged
again under the same conditions. The pellet was then resuspended with the
addition of 0.9 mg DDM per 1 mg of protein and centrifuged under the same
conditions once more. The supernatant containing solubilized membrane
proteins was collected.
Purification of Cytochrome bc1. The solubilized proteins were loaded on
a DEAE-Sepharose CL-6B (Sigma-Aldrich) column (approximately 50 mL)
preequilibrated with buffer A (50 mM KPi pH 7.5; 250 mMNaCl; 0.03% DDM;
3 mM NaN3), then washed with 2 column volumes (CVs) of buffer A and
eluted along a linear gradient from 250 mM to 500 mM NaCl. The cyto-
chrome bc1-containing fractions were pooled together before being diluted
twofold with buffer C (50 mM KPi pH 7.5; 0.03% DDM; 3 mM NaN3). The
protein solution was then applied to a hydroxyapatite (Bio-Rad) column
(approximately 15 mL), washed with 10 CVs of buffer C before elution with
the gradient from 50 mM to 1 M KPi (pH 7.5). Fractions containing cyto-
chrome bc1 were then concentrated to approximately 500 μL, using an
Amicon Ultra-15 (Millipore, MWCO 100,000). The concentrated protein was
then applied to a Sephacryl-S300 (GE Healthcare) column (approximately
120 mL) preequilibrated with buffer D (25 mM KPi (pH 7.5); 100 mM NaCl;
0.015% DDM; 3 mM NaN3) and eluted at a flow rate of 0.5 mL/min.
Crystallization of Cytochrome bc1. Inhibitors dissolved in DMSO solution at
a stock concentration of 10 mM were added to cytochrome bc1 in 10-fold
molar excess and incubated at 4 °C for one hour. Remaining DMSO and
inhibitors were removed via buffer exchange on an Amicon Ultra-4 (Millipore,
MWCO 100,000) and the protein was concentrated to 30 mg/mL in 25 mM
KPi (pH 7.5), 100 mM NaCl, 0.015% DDM, 3 mM NaN3. Crystallization was pre-
formed at 4 °C by sitting drop vapor diffusion method over reservoir solution
containing 50 mM KPi (pH 6.4–7.2), 100 mMNaCl, 3 mMNaN3, 10–13% PEG4000
and 0.14% 6-O-(N-Heptylcarbamoyl)-methyl-α-D-glucopyranoside (HECAMEG).
Drops were made to 10 μL with 1:1 ratio of protein to precipitant. Crystals
appeared overnight among precipitation and were allowed to grow before
being flash frozen in 25% (vol/vol) glycerol.
Data Collection, Processing, Model Building, and Refinement. Data collection
statistics can be found in Table 1. Multiple crystals from the same drop were
tested at 100 K using a home source FRE+ andMar225 CCD at the Barkla X-ray
Laboratory in Liverpool before transport to SOLEIL PROXIMA1 and Diamond
Light Source IO4 beamline. Datasets from multiple crystals belonging to the
same P65 space group and unit cell were collected at 100 K using a 1-Å beam
before being scaled and merged together using DENZO in the HKL2000 suite
(49). Molecular replacement was carried out using pdb: 1PPJ as a starting
model (42) in MOLREP (50) followed by rigid body refinement in Refmac5
(51). Cycles of automatic refinement were carried out using Refmac 5 with
Prosmart restraints and manual input was done with COOT (52). Ligands
were produced in JLigand and added manually (53). Pyridones were placed
in both Qi sites of the dimer with equal confidence. Two-dimensional
pharmacophores of both GSK932121 and GW844520 were produced using
LigPlot+ (54).
Sequence Alignment. Protein sequences for cytochrome b of various species
were taken from the UniProtKB and aligned using ClustalOmega (55). The
alignment was visualized using JalView 2.8 and additional annotations were
added using GIMP.
Reverse Crabtree-Effect Cellular Toxicity Studies. Cellular toxicities were de-
termined based on the method of Marroquin et al. (46) modified by Warman
et al. (56), Briefly, HepG2 cells cultured in glucose media (high-glucose
DMEM containing 25 mM glucose, 1 mM sodium pyruvate, 5 mM Hepes,
10% FBS, and 100 μg/mL penicillin/streptomycin) or galactose media (as per
glucose media but using glucose-free DMEM) were added to 96-well plates
(100 μL, 1 × 104 cells per well) and incubated for 24 h at 37 °C. The test
compounds were added and incubation continued for an additional 24 h.
The plates were subsequently incubated for 2 h in the presence of 1 mg/mL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution. Solubi-
lization buffer, consisting of 50% (vol/vol) N,N-dimethylformamide and 20%
(wt/vol) SDS, was added before well absorbance at 560 nm was measured
using a Varioskan plate reader (Thermo Scientific). Experiments were per-
formed in triplicate and repeated on three or more independent occasions.
The IC50 values were determined using a four-parameter logistic function.
Chemistry. ELQ 300 was prepared as described by Nilsen et al. using (4-
(trifluoromethoxy) phenyl) boronic acid as starting material (57). GW844520
was prepared as outlined by Yeates et al. (34). GSK932121 was prepared in
six steps from intermediate 2, according to Bueno et al. (33). (For the syn-
thesis of 2, see the route developed by Liu et al. (58).
Molecular Docking. Three-dimensional structures of the compounds docked
were created via energy minimization using the Merck molecular force field
Table 1. Data collection and refinement statistics
Data collection and
refinement bc1-GW844520 bc1-GSK932121
Space group P 65 P 65
Cell dimensions
a, b, c, Å 129.9. 129.9, 722.2 129.5, 129.5, 719.9
α, β, γ, ° 90, 90, 120 90, 90, 120
Resolution (Å) 50–3.55 (3.68–3.58) 50–4.09 (4.25–4.09)
Rmerge 23.8 (100) 14.7 (50.6)
I/σI 7.01 (1.83) 6.03 (1.78)
Completeness (%) 100 (100) 80.7 (51.5)*
Redundancy 8 (7) 3.2 (2.6)
Refinement
Resolution, Å 50–3.55 50–4.09
No. reflections 77,417 40,901
Rwork/Rfree 20.60/25.16 22.33/27.11
Nonhydrogen atoms
Protein 30,376 30,365
4(1H)-Pyridone 28 29
Other ligands 686 688
B factors
Protein 141.90 170.01
4(1H)-Pyridone 157.90 173.20
Other ligands 135.54 159.57
Rms deviations
Bond lengths, Å 0.011 0.013
Bond angles, ° 1.695 1.454
PDB access codes 4D6T 4D6U
*Values in parentheses are for highest-resolution shell. The density sup-
porting the positioning of the compound is still strong despite the low
completeness.
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(MMFF) 94 (59) within the SPARTAN ’08 1.2.0 package. (Spartan ’08, Wave-
function, 2008; www.wavefun.com, accessed June 30, 14). All molecular dock-
ing was performed using the GOLD docking suite version 5.2 (60–62). A genetic
algorithm (GA) using piecewise linear potential (PLP) as the fitness function was
used for all docking calculations. Ten independent GA runs were performed for
each ligand. Default settings were used except the “allow early termination”
setting in the “fitness and search option” was turned off.
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